“This has been an area of debate because observational studies have shown a reduced risk of Alzheimer’s disease with hormone therapy use, while a randomized controlled trial showed an increased risk.
Our results suggest that there may be a critical window near menopause where hormone therapy may possibly be beneficial,” said study author Peter P. Zandi, PhD, with Johns Hopkins University in Baltimore. “On the other hand, if started later in life, hormone therapy could be associated with an increased risk of developing Alzheimer’s disease.”
For the study, researchers followed 1,768 women ages 65 and older for 11 years. The women provided a history of their hormone therapy use and the date at which menopause began. A total of 1,105 women had used hormone therapy, consisting of estrogen alone or in combination with a progestin. During the study, 176 women developed Alzheimer’s disease dementia, including 87 of the 1,105 women who had taken hormone therapy compared to 89 of the 663 others.
The study found that women who began hormone therapy within five years of menopause had a 30-percent lower risk of Alzheimer’s dementia than those who had not used hormone therapy. The risk was unchanged among other hormone users who had begun treatment more than five years after menopause, but a higher risk of dementia was observed among women who had started a combined therapy of estrogen and progestin when they were at least 65 years old.
“While this well-designed study supports the possibility that short-term hormone use may reduce the risk of Alzheimer’s disease, more research is needed before we can make new clinical recommendations for women and their use of hormone therapy,” said Victor Henderson, MD, MS, with Stanford University in Stanford, Calif., and a Fellow of the American Academy of Neurology, who wrote an accompanying editorial.
The study was supported by the National Institute on Aging.
To learn more about Alzheimer’s disease, visit http://www.aan.com/patients.
The American Academy of Neurology, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson’s disease and epilepsy.
For more information about the American Academy of Neurology, visit http://www.aan.com
Rachel L. Seroka | American Academy of Neurology
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences